We have seen in Epidermal Growth Factor Receptor (EGFR) mutated lung cancer that targeting with a small molecule inhibitor of EGFR can lead to impressive response rates and tumor control better than standard cytotoxic chemotherapy. The gene discussed is EGFR; the disease is lung carcinoma.